Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of oral fidrisertib (IPN60130) in fibrodysplasia ossificans progressiva
2024-511469-13-00Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of Fidrisertib in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoints: Annualized change from baseline in heterotopic ossification volume at Month 12 and Safety and tolerability. Started Oct 2021; status: completed.
02
Drugs
Fidrisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2024-511469-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511469-13-00.